APLP2 and mild neurocognitive disorder: However, the major sex differences we observed were limited to the End-stage of disease progression as little or no effects of APLP2 gene ablation were seen at the earlier symptomatic and pre-symptomatic stages in our MND mouse model classification which suggests little involvement of APLP2 prior to severe disease onset.